Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

(2010) C R Giver et al.   LEUKEMIA

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

(2009) G. H. S. Richter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

(2008) Leah A. Owen et al.   PLoS One